510(k) for BioStar's flu diagnostic kit:
This article was originally published in Clinica
The FDA has cleared BioStar's rapid test for influenza for sale in the US. FLU OIA uses an optical immunoassay technology, developed by the Santa Fe, New Mexico-based company, to detect both influenza A and influenza B within 20 minutes. The test was developed as a collaboration between BioStar, which was recently acquired by Thermo BioAnalysis, and Australian company Biota Holdings
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.